The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

BTIG: Upgrade Outlook Therapeutics ( Outlook Therapeutics, Inc.(OTLK.US) ) to "Buy", with a price target of $4.

TD Cowen: Maintaining a "buy" rating on Nakamoto ( Nakamoto Inc.(NAKA.US) ), while raising the price target from $1 to $17.

HC Wainwright & Co.: Maintaining a "buy" rating on Nuvation Bio ( NUVATION BIO INC(NUVB.US) ), with a price target raised from $17 to $21.

LUCID CAPITAL MARKETS: Polaryx Therapeutics ( Polaryx Therapeutics, Inc.(PLYX.US) ) has a preliminary rating of "Buy", with a target price of $7.

RBC Capital: Maintaining its "Outperform" rating for Legend Biotech ( Legend Biotech(LEGN.US) ), while lowering its price target from $63 to $59.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
Outlook Therapeutics, Inc.(OTLK.US)	to lift	$4.0	$1.065	275.59%	BTIG
Nakamoto Inc.(NAKA.US)	to lift	$17.0	$4.69	262.47%	TD Cowen
NUVATION BIO INC(NUVB.US)	to lift	$21.0	$6.66	215.32%	HC Wainwright & Co.
Cerebras Systems(CBRS.US)	to lift	$310.0	$188.61	64.36%	Mizuho
Canadian National Railway Company(CNI.US)	to lift	$205.0	$128.88	59.06%	RBC Capital
Polaryx Therapeutics, Inc.(PLYX.US)	Initial classification	$7.0	$1.96	257.14%	LUCID CAPITAL MARKETS
Legend Biotech(LEGN.US)	cut	$59.0	$19.27	206.18%	RBC Capital
Charter Communications, Inc. Class A(CHTR.US)	cut	$380.0	$131.61	188.73%	TD Cowen
Zevra Therapeutics, Inc.(ZVRA.US)	cut	$24.0	$9.71	147.17%	Guggenheim
Zevra Therapeutics, Inc.(ZVRA.US)	cut	$20.0	$9.71	105.97%	Canaccord Genuity

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Wedbush: Maintaining its "outperform" rating for Advanced Micro Devices, Inc.(AMD.US) stock, while raising its price target from $450 to $600.

Mizuho: Maintaining a "neutral" rating on GE Vernova ( GE Vernova Inc.(GEV.US) ), while raising its price target from $913 to $949.

Wells Fargo: Upgraded Sirius XM Holdings ( Sirius XM Holdings Inc.(SIRI.US) ) stock to "Market-equal weight," with a price target of $30.

TD Cowen: Maintaining a "Hold" rating on Western Alliance Bancorporation ( Western Alliance Bancorp(WAL.US) ), while raising the price target from $89 to $90.

First Coverage

JP Morgan: Bending Spoons ( Bending Spoons S.p.A.(BSP.US) ) has a "neutral" initial rating, with a $35 price target.

Keybanc: Neutron Holdings ( Neutron Holdings, Inc.(LIME.US) ) has an initial rating of "overweight", with a target price of $33.

Citizens: Initial rating for Sonida Senior Living ( Sonida Senior Living, Inc.(SNDA.US) ) at "Outperform," with a price target of $50.

reduction

RBC Capital: Maintaining its "Outperform" rating for FTAI Aviation ( FTAI Aviation Ltd.(FTAI.US) ), while lowering its price target from $350 to $300.

Baird: Maintaining a "neutral" rating on HCA Healthcare ( HCA Healthcare Inc(HCA.US) ), while lowering the price target from $396 to $393.

Goldman Sachs: Downgraded Vale ( Vale S.A. Sponsored ADR(VALE.US) ) to "neutral", with a price target cut from $18 to $16.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.